Current Results of a Multicenter Trial in Multiple Myeloma

257 untreated myeloma patients (stage II and III) were studied in a multicenter trial. The patients were randomized and received MP or VCMP therapy. No differences in remission rate could be found in both therapy arms. After successful remission induction those patients without maintenance therapy relapsed significantly earlier than those patients receiving maintenance therapy. In pilot studies an etoposide therapy was found ineffective and a multidrug therapy (VBAMDex) could induce high remission rates in high risk and pretreated patients.
Zusammenfassung und Schlüsselwörter


Multiples Myelom – Randomisierte Studie – Erhaltungstherapie

Prospective Randomized Trial in Stage II and III Multiple Myeloma: MP Versus VCMP

257 untreated myeloma patients (stages II and III) were randomized into two treatment groups: group 1 treated with melphalan 8mg/m² p.o. plus prednisone 60mg/m² p.o. d. 1-4 Q four weeks [1] and group 2 treated with vincristine 1 mg i.v. d. 1, cyclophosphamide 100mg/m² p.o., melphalan 5mg/m² p.o., and prednisone 60mg/m² p.o. d. 1-4 Q four weeks [2]. Data from 171 patients were available after induction therapy (6 cycles). The clinical course was compared with the tumor mass change calculated by the method of Salmon and Wampler [3] and a good correlation could be found. The effect of both therapy schemes was equal in both groups of patients (64% complete and partial remission, 21% no change, 15% tumor progress). No differences in remission rates were observed between stage II or stage III patients. Patients with remission were randomized into no maintenance, or maintenance therapy consisting of identical chemotherapy cycles Q eight weeks. Data from 52 patients could be evaluated. Patients without maintenance therapy relapsed significantly more frequently than patients receiving maintenance therapy, but the influence of early relapse on patient’s life time remains to be determined.

dexamethasone 25mg/m² i.v. d. 1-4, 15-18, 29-32, 43-46, Q eight weeks. 10 patients (7 stage III patients) were untreated; 3 patients were pretreated with one and 7 patients with more than one chemotherapy protocol. 18 patients were IgG or IgA myelomas and their change in tumor mass was calculated using the method of Salmon and Wampler [3]. One Bence Jones myeloma and one patient with a nonsecretory myeloma were judged by radiological and clinical data. The effect of the combination was evaluated after at least one complete cycle of chemotherapy. 7 patients reached a partial remission (25-75% reduction of tumor mass) and 11 patients a complete remission (more than 75% reduction of tumor mass) under this chemotherapy. No change of tumor mass was observed in two patients; progression did not occur. Hematotoxicity requiring dose reduction has been seen in 10 patients. We conclude that VBAMDex is a very effective combination both for untreated and for pretreated high risk myeloma patients.

Pilot Study Etoposide Monotherapy

Thirteen myeloma patients were treated in a pilot study with etoposide 120mg/m² i.v. d. 1, 2 and 3, Q three weeks. 10 patients were pretreated with one, 3 patients with more than one chemotherapy protocol. Nine of these patients were IgG or IgA myelomas and their change in tumor mass was calculat-

Pilot Study VBAMDex

Twenty myeloma patients were treated in a pilot study with vincristine 1mg/m², adriamycin 15mg/m², and melphalan 7mg/m² i.v. d. 1, 15, 29, 43; BCNU 40mg/m² i.v. d. 1, and
ed using the method of Salmon and Wampler [3]. Four Bence Jones myelomas were judged using radiological and clinical data. The effect of etoposide therapy was evaluated after at least three cycles of chemotherapy. The tumor progressed in 8 patients, 5 patients showed no change in tumor mass. No remission was observed. These data show that etoposide as a single agent is ineffective, at least in pretreated myeloma patients.

References